Dengue virus and dengue fever

doi:10.3969/j.issn.1006-7795.2014.06.001

Abstract

Abstract:

Dengue fever(DF) is the most widespread mosquito-borne diseases worldwide, caused by Dengue virus(DV). There are nearly half of the world's populations at the risk of infection in tropical and subtropical countries. DF is divided into Dengue and severe Dengue, which include Dengue hemorrhagic fever(DHF) and Dengue shock syndrome(DSS). With an estimated 500 000 cases of life-threatening disease in the form of severe Dengue every year, most of them are children. Notably, there is the most serious DF outbreak in southern China at 2014. This review will summarize several aspects of Dengue virus and Dengue fever to provide the information to the colleagues.

Key words: Dengue fever, Dengue virus, sever Dengue, infection

CLC Number:

R512.8

Cui Xiaoyun, Wu Yanhua, An Jing. Dengue virus and dengue fever[J]. Journal of Capital Medical University, 2014, 35(6): 683-688.

References

[1] Bhatt S, Gething P W, Brady O J, et al. The global distribution and burden of Dengue[J]. Nature, 2013,496(7446):504-507.
[2] World Health Organization. Global strategy for Dengue prevention and control 2012-2020[M]. World Health Organization, 2012.
[3] Guzman M G, Halstead S B, Artsob H, et al. Dengue: a continuing global threat[J]. Nature Rev Microbiol, 2010,8(12 Suppl):S7-S16.
[4] 广东CDC.我省全力做好登革热疫情防控工作续报四[EB/OL].[2014-10-21]. http://www.cdcp.org.cn/gdsibytkzzx/gnwxx001/201410/12.
[5] Perera R, Khaliq M, Kuhn R J. Closing the door on flaviviruses: entry as a target for antiviral drug design[J]. Antiviral Res, 2008,80(1):11-22.
[6] Calisher C H, Karabatsos N, Dalrymple J M, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera[J]. J Gen Virol, 1989,70(1):37-43.
[7] Flipse J, Wilschut J, Smit J M. Molecular mechanisms involved in antibody-dependent enhancement of Dengue virus infection in humans[J]. Traffic, 2013,14(1):25-35.
[8] Kostyuchenko V A, Chew P L, Ng T S, et al. Near-atomic resolution cryo-electron microscopic structure of Dengue serotype 4 virus[J]. J Virol, 2014,88(1):477-482.
[9] Wu N, Gao N, Fan D, et al. miR-223 inhibits Dengue virus replication by negatively regulating the microtubule-destabilizing protein STMN1 in EAhy926 cells[J]. Microbes and Infection, 2014,16(11):911-922.
[10] Hussain M, Asgari S. MicroRNA-like viral small RNA from Dengue virus 2 autoregulates its replication in mosquito cells[J]. Proc Natl Acad Sci, 2014,111(7):2746-2751.
[11] Gutsche I, Coulibaly F, Voss J E, et al. Secreted Dengue virus nonstructural protein NS1 is an atypical barrel-shaped high-density lipoprotein[J]. Proc Natl Acad Sci, 2011,108(19):8003-8008.
[12] Cui T, Sugrue R J, Xu Q, et al. Recombinant Dengue virus type 1 NS3 protein exhibits specific viral RNA binding and NTPase activity regulated by the NS5 protein[J]. Virology, 1998,246(2):409-417.
[13] Fraser J E, Rawlinson S M, Wang C, et al. Investigating Dengue virus nonstructural protein 5(NS5) nuclear import[M]. Dengue. Springer New York: 2014:301-328.
[14] World Health Organization. Dengue and severe Dengue[EB/OL].[2014-10-21]. http://www.who.int/mediacentre/factsheets/fs117/en/2014.03.
[15] Webster D P, Farrar J, Rowland-Jones S. Progress towards a Dengue vaccine[J]. Lancet Infectious Dis, 2009,9(11):678-687.
[16] Green S, Rothman A. Immunopathological mechanisms in Dengue and Dengue hemorrhagic fever[J]. Comp Immunol Microbiol Infect Dis, 2006,19(5):429-436.
[17] Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis[J]. Comp Immunol Microbiol Infect Dis, 2007,30(5):329-340.
[18] Pérez A B, García G, Sierra B, et al. IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba[J]. J Med Virol, 2004,73(2):230-234.
[19] Sariol C A, White L J. Utility, limitations, and future of non-human primates for Dengue research and vaccine development[J]. Front Immunol, 2014,5:452.
[20] Shresta S, Kyle J L, Snider H M, et al. Interferon-dependent immunity is essential for resistance to primary Dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical[J]. J Virol, 2004,78(6):2701-2710.
[21] Rajmane Y, Shaikh S, Basha K, et al. Infant mouse brain passaged Dengue serotype 2 virus induces non-neurological disease with inflammatory spleen collapse in AG129 mice after splenic adaptation[J]. Virus Res, 2013,173(2):386-397.
[22] Williams K L, Zompi S, Beatty P R, et al. A mouse model for studying Dengue virus pathogenesis and immune response[J]. Ann NY Acad Sci, 2009,1171(s1):E12-E23.
[23] Johnson A J, Roehrig J T. New mouse model for Dengue virus vaccine testing[J]. J Virol, 1999,73(1):783-786.
[24] Prestwood T R, Morar M M, Zellweger R M, et al. Gamma interferon(IFN-γ) receptor restricts systemic Dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice[J]. J Virol, 2012,86(23):12561-12570.
[25] Zellweger R M, Shresta S. Mouse models to study Dengue virus immunology and pathogenesis[J]. Front Immunol, 2014,5:151.
[26] Bente D A, Rico-Hesse R. Models of Dengue virus infection[J]. Drug Discov Today Dis Models, 2006,3(1):97-103.
[27] Wu S J, Hayes C G, Dubois D R, et al. Evaluation of the severe combined immunodeficient(SCID) mouse as an animal model for Dengue viral infection[J]. Am J Trop Med Hyg, 1995,52(5):468-476.
[28] An J, Kimura-Kuroda J, Hirabayashi Y, et al. Development of a novel mouse model for Dengue virus infection[J]. Virology, 1999,263(1):70-77.
[29] Blaney Jr J E, Johnson D H, Manipon G G, et al. Genetic basis of attenuation of Dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells[J]. Virology, 2002,300(1):125-139.
[30] Phoolcharoen W, Smith D R. Internalization of the Dengue virus is cell cycle modulated in HepG2, but not Vero cells[J]. J Med Virol, 2004,74(3):434-441.
[31] Serreze D V, Leiter E H, Worthen S M, et al. NOD marrow stem cells adoptively transfer diabetes to resistant(NOD× NON) F1 mice[J]. Diabetes, 1988,37(2):252-255.
[32] Bente D A, Melkus M W, Garcia J V, et al. Dengue fever in humanized NOD/SCID mice[J]. J Virol, 2005,79(21):13797-13799.
[33] Williams K L, Zompi S, Beatty P R, et al. A mouse model for studying Dengue virus pathogenesis and immune response[J]. Ann NY Acad Sci, 2009,1171(s1):E12-E23.
[34] Roberts C H, Mongkolsapaya J, Screaton G. New opportunities for control of Dengue virus[J]. Curr Opin Infect Dis, 2013,26(6):567-574.
[35] Fuchs J, Chu H, Peter O D, et al. Investigating the efficacy of monovalent and tetravalent Dengue vaccine formulations against DENV-4 challenge in AG129 mice[J]. Vaccine, 2014,32(48):6541-6543.
[36] Guy B, Barrere B, Malinowski C, et al. From research to phase Ⅲ: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent Dengue vaccine[J]. Vaccine, 2011,29(42):7229-7241.
[37] Capeding M R, Tran N H, Hadinegoro S R S, et al. Clinical efficacy and safety of a novel tetravalent Dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial[J]. The Lancet, 2014,384(9951):1358-1365.
[38] Riedmann E M. Human vaccines & immunotherapeutics: news[J]. Hum Vaccin Immunother, 2014,10(6):1427-1430.
[39] Malavige G N, Fernando S, Fernando D J, et al. Dengue viral infections[J]. Postgrad Med J, 2004,80(948):588-601.
[40] Mizuno Y, Kotaki A, Harada F, et al. Confirmation of Dengue virus infection by detection of Dengue virus type 1 genome in urine and saliva but not in plasma[J]. Trans R Soc Trop Med Hyg, 2007,101(7):738-739.
[41] Poloni T R, Oliveira A S, Alfonso H L, et al. Detection of Dengue virus in saliva and urine by real time RT-PCR[J]. Virol J, 2010,7:22.
[42] Mousson L, Dauga C, Garrigues T, et al. Phylogeography of Aedes(Stegomyia) aegypti(L.) and Aedes(Stegomyia) albopictus(Skuse)(Diptera: Culicidae) based on mitochondrial DNA variations[J]. Genetical Res, 2005,86(1):1-11.